Radiation therapy is one of the cornerstones of cancer treatment. About 50% to 60% of all cancer patients receive radiation therapy at some point during their care, according to AdvaMed, and it contributes to roughly 40% of all curative cancer treatment regimens worldwide. [Source: AdvaMed] But radiation therapy has a persistent limitation that oncologists have grappled with for decades. It works well against well-oxygenated tumor tissue. Against oxygen-deprived regions inside a tumor, it often doesn’t work nearly as well. That’s where nitric oxide enters the picture. Researchers have been studying NO’s relationship with radiation therapy for over 30 years, examining how this naturally produced molecule interacts with tumor biology, how it might make radiation more effective, and what it does to the immune system during and after treatment. Here’s what the science actually says.
Radiation therapy uses high-energy beams, X-rays, protons, or gamma rays, to damage the DNA inside cancer cells. When DNA is broken beyond repair, the cell can no longer divide and eventually dies. The process isn’t purely mechanical. It depends heavily on oxygen. When radiation hits tissue, it generates highly reactive molecules called free radicals. Those free radicals bind to oxygen and create the chemical chain reaction that permanently damages cancer cell DNA. Without adequate oxygen present at the moment of irradiation, that chain reaction is incomplete. The cancer cell can repair the damage and survive. This is the oxygen problem at the heart of radiation oncology.
Tumor hypoxia simply means oxygen-deprived areas within a tumor. It develops because tumors grow faster than their blood supply can keep up with, leaving regions of tissue that are chronically under-oxygenated. It’s not a rare edge case. According to a review published in PMC (NIH), hypoxia is one of the most frequent hallmarks of solid tumors, appearing in approximately 90% of cases. Normal tissues exist at 2–9% oxygen. Hypoxic tumor regions can drop to between 0.02% and 2% oxygen, sometimes lower. [Source: PMC/NIH] The practical consequence for treatment is significant. Research published in Frontiers in Applied Mathematics and Statistics confirms that well-oxygenated tumor regions show up to three-fold greater radiosensitivity than hypoxic tumor populations. [Source: Frontiers] That is a massive gap. Hypoxic cancer cells can require up to three times the radiation dose to achieve the same cell death as an oxygenated cell. And in most solid tumors, those hypoxic regions are the ones most likely to survive, regrow, and metastasize. A review published in ScienceDirect put it plainly: hypoxia in solid tumors is “an important predictor of poor clinical outcome to radiotherapy,” with tumor hypoxia remaining “a major hurdle for successful treatment outcome” even with modern fractionated radiation regimens. [Source: ScienceDirect]
This is the core of the article, and the reason researchers have invested so much in understanding NO’s relationship with radiation. Nitric oxide is described in biomedical literature as a radiosensitizer, a substance that makes tumor cells more susceptible to radiation damage. What makes NO particularly interesting is that it mimics oxygen’s role in fixing radiation-induced DNA damage, even in the absence of adequate oxygen. In other words, NO can potentially do in a hypoxic environment what oxygen normally does in a well-perfused one.
An AACR-published study in Cancer Research stated plainly: “Nitric oxide (NO) is an alternative hypoxic cell radiosensitizer that has shown great clinical potential. NO is a highly reactive electrophile that is cytotoxic in the absence of oxygen. It is the second most potent chemical radiosensitizer.” [Source: AACR / Cancer Research] Second only to oxygen itself. That’s not a fringe claim; it’s coming from peer-reviewed oncology research published by the American Association for Cancer Research.
Nitric oxide addresses the hypoxia problem through two related mechanisms: First, NO is a powerful vasodilator. It relaxes the smooth muscle around blood vessel walls, increasing blood flow and perfusion into tumor tissue. More blood flow means more oxygen delivery, directly reducing the hypoxic zones that protect cancer cells from radiation. Second, NO can independently mimic the oxygen-fixation effect. When radiation hits a cell, it creates unstable free radicals. Normally, oxygen reacts with those radicals to permanently “fix” (lock in) the DNA damage. NO can substitute for oxygen in this reaction, accomplishing the same damage fixation even in cells where oxygen levels are too low for the process to work naturally. Research published in PubMed (NIH) on an animal tumor model confirmed this directly: ionizing radiation upregulated NO production, which then increased intratumoral circulation, improved tissue oxygenation, and decreased the hypoxic regions in tumors, with NOS inhibition reversing these effects. [Source: PubMed/NIH]
One of the most studied mechanisms behind NO’s potential role in radiation therapy involves a protein called p53, one of the body’s primary tumor suppressors. Research published in Cancer Research (AACR) found that NO and ionizing radiation synergistically activate p53 in colorectal cancers. They do this by augmenting phosphorylation of p53 at a specific site (serine 15), which triggers a cascade leading to cancer cell apoptosis, programmed death. Critically, this synergy was significantly reduced in p53 knockout cancer cell lines, confirming that p53 activation is a primary mechanism driving the combined effect of NO and radiation. In lab studies using iNOS gene transfer into colorectal tumors:
AdiNOS (adenoviral iNOS) plus radiation led to a 3.4-fold greater tumor growth delay compared with radiation alone
63% of treated tumors regressed with the combination, compared with only 6% with radiation alone [Source: AACR / Cancer Research | PubMed/NIH – iNOS gene transfer in colorectal cancer]
Those are striking numbers from controlled preclinical work. They’re not clinical trial results in humans, but they explain clearly why this research direction has continued to attract serious attention.
The challenge with nitric oxide as a therapeutic agent has always been control. NO diffuses rapidly in all directions. Delivering it specifically to a tumor, in the right concentration, at the right time, is technically demanding. That’s why a major focus of current research is NO-releasing nanoparticles: engineered delivery systems designed to carry NO donors into tumor tissue and release them precisely where and when they’re needed. Research published in ACS Biomaterials Science & Engineering tested a system where radiation-activated nanoparticles (NSC@SiO₂-SNO NPs) carrying NO donors were concentrated in tumors. Under radiation exposure, they released high concentrations of NO specifically within the tumor. Both in vitro and in vivo studies showed the nanoagents effectively reduced tumor hypoxia, promoted radiation-induced apoptosis and DNA damage under hypoxia, and ultimately inhibited tumor growth. [Source: ACS Biomaterials Science & Engineering] A separate approach, tested for glioblastoma brain tumors, used NO donors loaded into nanoformulations that could cross the blood-brain barrier. Radiation triggered a threepronged effect: dose enhancement, NO-mediated hypoxia relief, and hypoxia-selective cancer cell killing, significantly inhibiting glioblastoma growth in preclinical models. [Source: Cancer Nanotechnology / BioMed Central] This is the frontier of the field, highly targeted, radiation-triggered NO delivery that avoids the systemic side effects that have historically limited clinical use of NO in this context.
This is an often-overlooked part of the radiation therapy conversation. The treatment doesn’t just affect the tumor. It affects the immune system too, sometimes significantly.
Radiation therapy can cause radiation-induced lymphopenia (RIL), a drop in circulating lymphocyte counts that weakens immune defenses. According to a PMC/NIH review, severe RIL occurs in 30–50% of patients with solid tumors and is most severe after radiotherapy targeting the brain, thorax, and upper abdomen. The same review found that multiple meta-analyses show a pooled hazard ratio of 1.65 for the negative impact of severe RIL on overall survival in solid tumor patients, meaning patients who develop severe lymphopenia after radiation have meaningfully worse survival outcomes on average. [Source: PMC/NIH] A PubMed study measuring immune changes in 14 breast cancer patients after radiation also found decreases in natural killer (NK) cell functional activity, monocyte phagocytic activity, and lymphocyte counts, with lymphocyte counts not returning to normal by the end of a 6-week post-radiation observation period. [Source: PubMed/NIH] This immune suppression matters. It’s the window during which infection risk rises, and when the immune system’s ability to identify and destroy residual cancer cells is reduced.
Here’s where the biology gets genuinely interesting. Nitric oxide is not just a potential radiosensitizer. It also plays a direct role in how the immune system responds during and after radiation. Research published in MDPI’s Cancers journal, and confirmed across multiple publications, found that in response to local low-dose ionizing radiation, iNOS-positive M1-like macrophages undergo differentiation — a process that leads to recruitment of tumorspecific T cells and tumor regression in human pancreatic carcinomas. [Source: MDPI / Cancers] The same finding was confirmed in research published in the British Journal of Clinical Pharmacology (Wiley): low-dose ionizing radiation triggers the differentiation of iNOS+ M1-like macrophages, driving tumor-specific T cell recruitment and tumor regression. [Source: British Journal of Clinical Pharmacology / Wiley]
In plain terms: nitric oxide, produced by immune cells called macrophages in response to low-dose radiation, appears to be part of the mechanism by which the immune system turns radiation-killed cancer cells into an anti-tumor immune response. NO connects the killing of cancer cells by radiation to the broader immune activation that can help the body continue fighting residual disease. And research in Frontiers in Immunology (2026) further confirmed that low-dose radiation favors M1-like macrophage polarization, with increased iNOS activity and nitric oxide production, normalizing tumor vasculature, reducing pro-angiogenic signaling, and improving T-cell infiltration into the tumor microenvironment. [Source: Frontiers in Immunology]
It would be a mistake to walk away from this article thinking NO is simply pro-radiationtherapy in every scenario. As covered in detail in the broader NO-cancer literature, nitric oxide’s behavior is concentration-dependent and context-dependent. At high concentrations in tumor tissue, it radiosensitizes and triggers apoptosis. In some contexts, particularly involving immunosuppressive myeloid cells in the tumor microenvironment, NO can actually impair T-cell function by blocking interleukin-2 receptor signaling, an effect that researchers are actively working to address. A PMC/NIH study found that combining radiotherapy with iNOS inhibition (blocking NO from immunosuppressive myeloid cells) increased tumor-infiltrating CD8+ T cells and improved survival in lung and breast cancer models, showing that in certain contexts, reducing NO from specific cells can also improve radiation outcomes. [Source: PMC/NIH]
This reflects the larger truth of NO biology: it’s not the molecule that’s good or bad. It’s which cells produce it, in what concentration, and in what microenvironment. The science is complex because the biology is complex, and any credible discussion of this topic has to acknowledge that.
Clinical NO therapy is being developed in research institutions. That’s not the same conversation as what patients undergoing radiation therapy can do right now to support their body’s immune function. The immune system takes a real hit during radiation treatment. Lymphopenia, reduced NK cell activity, decreased macrophage function; these are documented, measurable effects. And they compound an already common problem: nitric oxide production naturally declines with age, leaving many patients entering radiation treatment with a weakened immune foundation before treatment even begins. According to PMC (NIH), enzymatic NO production declines steadily with increasing age in healthy human subjects, a finding that has direct implications for immune resilience. [Source: PMC/NIH] Supporting natural NO production through diet and lifestyle, beets and beet juice, leafy greens (spinach, arugula, kale), watermelon, garlic, and L-arginine-rich foods like nuts, is backed by solid nutritional research and is accessible to most patients. Light aerobic activity, where treatment allows, also stimulates eNOS activity in blood vessels.
Radiation therapy is one of oncology’s most powerful tools, but tumor hypoxia has long blunted its effectiveness in a meaningful percentage of solid tumors. Nitric oxide, the body’s own signaling molecule, is a scientifically credible candidate for addressing that hypoxia problem, working both as a radiosensitizer and as part of the post-radiation immune response. The research spans peer-reviewed journals from AACR, NIH, and top-tier cancer research institutions. It is real science, published over decades, now accelerating toward more practical clinical applications through nanoparticle delivery systems and precision radiation approaches. It’s also a biology that’s genuinely complex – context-dependent, concentrationdependent, and still being worked out in clinical trials. Anyone navigating cancer treatment deserves to understand that nuance, not a simplified version of it.